Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4737 - Development and validation of novel nomograms predicting survival of malignant ependymoma patients: A population-based study


28 Sep 2019


Poster Display session 1


Tumour Site

Central Nervous System Malignancies


Alzhraa Abbas


Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243


A.S. Abbas1, M. Dibas2, S. Ghozy3

Author affiliations

  • 1 Faculty Of Medicine, Minia University, 2100 - Minia/EG
  • 2 College Of Medicine, Sulaiman Al-Rajhi Colleges, 1122 - Qassim/SA
  • 3 Neurosurgery Department, El Sheikh Zayed Specialized Hospital, 2170 - Giza/EG


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4737


Malignant ependymomas are one of the main types of glioma that have high morbidity and mortality. The objective of this study was to construct, validate and calibrate novel nomograms for the survival of ME patients.


We utilized the Surveillance, Epidemiology, and End Results database (SEER) to retrieve patients with ME. We excluded patients with an unknown diagnosis, no follow up or with autopsy report only. Moreover, we utilized penalized regression models (PRM) by using “hdnom” package in R with the highest AUC and the most stable calibrations to build nomograms for overall (OS) and cancer-specific survival (CSS).


Data of 3435 patients were retrieved and analyzed. We developed 18 PRM and chose Snet and SCAD for OS and CSS. These two models selected age, sex, year of diagnosis, marital status, site, race, type, surgery, radiation, and chemotherapy for the nomograms to be built. Our nomograms had stable calibrations with adequate to good accuracy AUC of 0.70 to 0.76 for the OS nomogram and AUC of 0.75 to 0.78 for the CSS nomogram.


In this population-based study, we developed nomograms that can better help physicians predict the prognosis and survival of ME patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Sherief Ghozy.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.